Phase 2 Pancreatic Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older who are male, or female and neither pregnant nor breastfeeding at the time of signing consent forms.
• People who are well enough to carry out most daily activities, as measured by a standard health performance scale (a score of 70% or higher on the Karnofsky scale, assessed within 7 days before enrolment).
• People whose pancreatic cancer has been confirmed by a tissue or cell sample (biopsy or similar test) as pancreatic adenocarcinoma.
• People whose tumour is classified as surgically removable ("resectable") based on specific guidelines (NCCN version 2.2021), confirmed by a contrast-enhanced CT or MRI scan of the chest, abdomen, and pelvis — meaning the tumour has not grown into certain major blood vessels or arteries, and there is no sign that the cancer has spread to other parts of the body.
• People with measurable disease on imaging scans, assessed within 28 days before enrolment, according to standard measurement criteria (RECIST v1.1).
• People who have not previously had surgery, radiation therapy, chemotherapy, targeted therapy, or any experimental treatment for pancreatic cancer.
• People whose blood, kidney, and liver test results fall within acceptable ranges when tested within 28 days before enrolment, including: sufficient white blood cell, red blood cell, and platelet counts; adequate kidney function; and bilirubin, AST, and ALT levels within acceptable limits.
• Females of childbearing potential who return a negative pregnancy test (blood or urine) within 3 days before enrolment.
• Females of childbearing potential who are willing to either abstain from vaginal intercourse or use an effective form of contraception from the time consent is given, throughout the study, and for 6 months after the last dose of study treatment. Males who are willing to either abstain from vaginal intercourse or use effective contraception from the start of treatment, throughout the study, and for 3 months after the last dose.
• People who are able to understand and follow all study procedures for the full duration of the trial, as determined by the enrolling doctor.
• People living with HIV who are on effective anti-retroviral treatment and have had an undetectable viral load within 6 months before enrolment.
• People with a history of hepatitis B (HBV) who are on suppressive therapy and have an undetectable viral load; and people with a history of hepatitis C (HCV) who have either been successfully treated and cured, or who are currently on treatment with an undetectable viral load.

Who may not be able to join:

• People whose cancer has spread to distant parts of the body (distant metastasis).
• People who have an electrical implanted device in their torso, such as a spinal cord stimulator, vagus nerve stimulator, pacemaker, or defibrillator.
• People with a history of significant, uncontrolled heart or cardiovascular disease — including certain types of heart block, significant heart disease, poorly controlled high blood pressure, or heart failure that limits everyday physical activity.
• People with a history of irregular heart rhythms (arrhythmia) that cause symptoms or require ongoing treatment (note: people with atrial fibrillation or flutter that is controlled by medication are not automatically excluded — confirm with trial site).
• People with a known allergy to medical adhesives or the type of conductive gel used on ECG stickers or TENS electrodes.
• People who are currently pregnant or breastfeeding.
• People with a previous or existing separate cancer whose history or required treatment could interfere with assessing the safety or effectiveness of this trial's treatments.
• People with other serious, uncontrolled medical conditions that, in the treating doctor's judgement, could create unacceptable risks or interfere with participation — for example, chronic pancreatitis, active hepatitis, or an untreated active infection.
• People with a prior cancer history, unless the cancer was adequately treated basal cell or squamous cell skin cancer, cervical cancer in situ, or another cancer for which the person has been free of both the disease and its treatment for at least two years.
• People who are unwilling or unable to follow the study procedures.

Important: Always verify eligibility with the trial site directly before applying.